Under normal market conditions, the fund invests at least 80% of its net assets (plus any borrowings for investment purposes) in equity securities issued by small and mid-capitalization companies. Its ...
CRANBURY, N.J., June 07, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor ...
CRANBURY, N.J., May 26, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, ...
Zacks Investment Research on MSN
PMV Pharmaceuticals (PMVP) loses 26% in 4 weeks, here's why a trend reversal may be around the corner
PMV Pharmaceuticals, Inc. (PMVP) has been on a downward spiral lately with significant selling pressure. After declining 26.1 ...
PMV Pharmaceuticals, Inc. reported a corporate update and financial results for the first quarter of 2025, focusing on the ongoing Phase 2 PYNNACLE clinical trial evaluating rezatapopt, a treatment ...
The tumor-suppressing protein p53 has long been considered a valuable target—if only drug hunters could figure out how to hit it. Many research efforts aiming to leverage the capabilities of this ...
PMV Pharmaceuticals is targeting a market that is served by AbbVie’s Elahere and AstraZeneca and Daiichi Sankyo’s Enhertu. (z_wei/iStock/Getty Images Plus) PMV Pharmaceuticals has reported a 43% ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results